Key result
Lipoprotein metabolism disorders linked to a ~50% rise in U.S. AMI mortality from 1999 to 2020.
Why the study?
Lipoprotein metabolism disorders contribute to residual cardiovascular risk following AMI, yet population-level mortality trends among U.S. adults remained poorly defined.
Observational (n=95,222)
Yes
AMI-related mortality among U.S. adults with lipoprotein metabolism disorders increased overall from 1999 to 2020 with a notable resurgence between 2018 and 2020, disproportionately affecting men, older adults, Non-Hispanic Whites and Blacks, and residents of non-metropolitan areas.
Answers are grounded in this paper and cite their sources.
Rising AMI mortality linked to lipoprotein disorders signals need for targeted prevention; leaves open whether interventions can reverse trends in high-risk groups.
Background Lipoprotein metabolism disorders (LMDs) contribute to residual cardiovascular risk following acute myocardial infarction (AMI), yet population-level mortality trends remain poorly defined. Objective To evaluate AMI-related mortality trends among U.S. adults with LMDs from 1999–2020. Methods A retrospective analysis of CDC WONDER data identified decedents aged ≥25 years with LMDs (ICD-10: E78) contributing to AMI (I21) as underlying cause. Age-adjusted mortality rates (AAMR) per 100,000 were analyzed using joinpoint regression, stratified by demographics. Results Among 95,222 deaths, overall AAMR rose from 3.27 (1999) to 4.91 (2020). Three phases emerged: increase (1999–2004; APC: 6.19), stability (2004–2018; APC: -0.39), and resurgence (2018–2020; APC: 6.82). Men had higher AAMR than women (2.88 vs. 1.31). Non-Hispanic Whites (2.1) and Blacks (2.04) showed highest rates; Asians/Pacific Islanders lowest (1.39). Older adults (65–85+ years) bore greatest burden (AAMR: 9.69). Geographically, Midwest (2.33) and West (2.22) exceeded South (1.88) and Northeast (1.77). Non-metropolitan areas had markedly higher AAMR than metropolitan areas (9.08 vs. 2.37). Most deaths occurred in medical facilities (54.65%) versus home (36.71%). Conclusion AMI-related mortality among U.S. adults with LMDs increased over two decades, with a concerning resurgence from 2018–2020 coinciding with the COVID-19 pandemic. Persistent disparities by sex, race, age, geography, and urbanization highlight urgent needs for targeted lipid management and equitable healthcare access to reduce cardiovascular mortality in this high-risk population.
No takes yet. Share an insight, caveat, or question.
Mustafa et al. (2026) conducted an observational in Acute myocardial infarction mortality with lipoprotein metabolism disorders (n=95,222). Lipoprotein metabolism disorders was evaluated on Age-adjusted mortality rate (AAMR) per 100,000 for acute myocardial infarction. Lipoprotein metabolism disorders were associated with an increase in U.S. AMI age-adjusted mortality rates from 3.27 per 100,000 in 1999 to 4.91 in 2020.
Synapse has enriched 10 related papers. Consider them for comparative context: